company background image
IMU

Imugene ASX:IMU Stock Report

Last Price

AU$0.18

Market Cap

AU$1.1b

7D

-2.7%

1Y

-64.7%

Updated

28 Nov, 2022

Data

Company Financials +
IMU fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IMU Stock Overview

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.

Imugene Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Imugene
Historical stock prices
Current Share PriceAU$0.18
52 Week HighAU$0.55
52 Week LowAU$0.13
Beta2.28
1 Month Change9.09%
3 Month Change-25.00%
1 Year Change-64.71%
3 Year Change350.00%
5 Year Change900.06%
Change since IPO84.61%

Recent News & Updates

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11
Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Recent updates

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11
Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22
Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28
Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17
A Look At Imugene's (ASX:IMU) CEO Remuneration

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24
Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Shareholder Returns

IMUAU BiotechsAU Market
7D-2.7%1.7%1.2%
1Y-64.7%-6.8%-2.9%

Return vs Industry: IMU underperformed the Australian Biotechs industry which returned -6.8% over the past year.

Return vs Market: IMU underperformed the Australian Market which returned -2.9% over the past year.

Price Volatility

Is IMU's price volatile compared to industry and market?
IMU volatility
IMU Average Weekly Movement10.9%
Biotechs Industry Average Movement8.9%
Market Average Movement9.0%
10% most volatile stocks in AU Market16.1%
10% least volatile stocks in AU Market4.2%

Stable Share Price: IMU is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: IMU's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1986n/aLeslie Chonghttps://www.imugene.com

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in Phase 1b/2 study for gastric cancer.

Imugene Limited Fundamentals Summary

How do Imugene's earnings and revenue compare to its market cap?
IMU fundamental statistics
Market CapAU$1.15b
Earnings (TTM)-AU$37.87m
Revenue (TTM)AU$12.97m

88.7x

P/S Ratio

-30.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMU income statement (TTM)
RevenueAU$12.97m
Cost of RevenueAU$0
Gross ProfitAU$12.97m
Other ExpensesAU$50.84m
Earnings-AU$37.87m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.0059
Gross Margin100.00%
Net Profit Margin-291.98%
Debt/Equity Ratio0%

How did IMU perform over the long term?

See historical performance and comparison